The present technology is directed generally to sensory threshold and/or adaptation for neurological therapy screening and/or parameter selection.
Neurological stimulators have been developed to treat pain, movement disorders, functional disorders, spasticity, cancer, cardiac disorders, and various other medical conditions. Implantable neurological stimulation systems generally have an implantable signal generator and one or more leads that deliver electrical pulses to neurological tissue or muscle tissue. For example, several neurological stimulation systems for spinal cord stimulation (SCS) have cylindrical leads that include a lead body with a circular cross-sectional shape and one or more conductive rings (i.e., contacts) spaced apart from each other at the distal end of the lead body. The conductive rings operate as individual electrodes and, in many cases, the SCS leads are implanted percutaneously through a needle inserted into the epidural space, with or without the assistance of a stylet.
Once implanted, the signal generator applies electrical pulses to the electrodes, which in turn modify the function of the patient's nervous system, such as by altering the patient's responsiveness to sensory stimuli and/or altering the patient's motor-circuit output. In SCS for the treatment of pain, the signal generator applies electrical pulses to the spinal cord via the electrodes. In conventional SCS, “low frequency” electrical pulses are used to generate sensations (known as paresthesia) that mask or otherwise alter the patient's sensation of pain. For example, in many cases, patients report paresthesia as a tingling sensation that is perceived as less uncomfortable than the underlying pain sensation.
In conventional SCS, the patients must first undergo a test (or “trial”) period to determine if they are responsive to the therapy before a permanent system is implanted. Responders are identified by meticulously programming multiple programs into an “external” patient-worn trial stimulator system, and instructing the patient to choose the most beneficial program for pain relief. Each of these multiple programs corresponds to stimulating a combination of two or more electrodes out of a total available set of 16 or more electrodes. Because paresthesia over large areas can result in discomfort for most patients, only a few electrodes are activated at a time in each program, to minimize the uncomfortable side effects for the patient. In addition, typical amplitude changes are small and controlled by a trained practitioner in order to avoid shocking the patient.
In contrast to conventional SCS, a form of “high frequency” SCS has been developed that uses high frequency electrical pulses delivered to the spinal cord to treat the patient's sensation of pain without generating paresthesia or otherwise using paresthesia to mask the patient's sensation of pain. Thus, conventional deployment methods, which rely on paresthesia for feedback, may not be adequate for deploying high frequency SCS systems. Accordingly, there is a need for methods of deploying high frequency SCS systems that account for the paresthesia-free aspects of high frequency therapy.
1.0 Overview
The present technology is directed generally to systems and methods for deploying patient therapy systems, including spinal cord stimulation (SCS) systems, and/or treating patients. For example, in a representative embodiment, the present technology is employed in SCS systems that provide pain relief without generating paresthesia, to identify, early on, those patients who respond favorably to the therapy. The technology can include detecting the patient's sensory threshold (and/or changes in the threshold), and using the detected threshold value(s) to identify patients likely to respond favorably to paresthesia free therapy. In addition to or in lieu of using sensory threshold to identify likely responders, such data can be used to identify which, among several candidate electrodes, is likely to produce better or optimal pain relief. This process is expected to take less time than stepping through many amplitudes during a trial period to determine which is best for the patient. Once the patient receives an implanted system, the manner in which the signal is delivered can be adjusted. For example, the duty cycle of the signal can then be reduced so as to reduce the power required by the implanted signal generator. In other embodiments, the patient's perceived intensity of the stimulus, and/or adaptation to the stimulus, can be used to distinguish likely responders from likely non-responders, and/or to select the parameter values for the therapeutic signal delivered to the patient.
In particular embodiments, the systems and methods disclosed herein are applicable to “high frequency,” paresthesia-free SCS systems. Such SCS systems, for example, inhibit, reduce, and/or eliminate pain via waveforms with high frequency elements or components (e.g., portions having high fundamental frequencies), generally with reduced or eliminated side effects. Such side effects can include unwanted motor stimulation and/or blocking, unwanted pain and/or discomfort, unwanted paresthesia, and/or interference with sensory functions other than the targeted pain. In representative embodiments, a patient receives high frequency therapeutic signals with at least a portion of the therapy signal at a frequency of from about 1.2 kHz to about 100 kHz, or from about 1.5 kHz to about 100 kHz, or from about 2.5 kHz to about 100 kHz, or from about 1.2 kHz to about 50 kHz, or from about 1.2 kHz to about 10 kHz, or from about 1.2 kHz to about 20 kHz, or from about 3 kHz to about 20 kHz, or from about 3 kHz to about 50 kHz, or from about 5 kHz to about 15 kHz, or at frequencies of about 8 kHz, 9 kHz, or 10 kHz. These frequencies are higher than the frequencies associated with standard conventional “low frequency” SCS, which are generally below 1,200 Hz, and more commonly below 100 Hz. Accordingly, stimulation at these and other representative frequencies (e.g., from about 1.2 kHz to about 100 kHz) is occasionally referred to herein as high frequency modulation or stimulation.
The disclosed embodiments can provide simplified procedures for initially determining if a patient is a responder. As used herein, the term “responder” refers generally to a patient who responds favorably to a particular therapeutic technique and/or system. Specific details of certain embodiments of the technology are described below with reference to methods for stimulating one or more target neural populations (e.g., nerves) or sites of a patient, and associated implantable and external structures for providing the stimulation. Although selected embodiments are directed to stimulating the dorsal column, dorsal horn, dorsal root, dorsal root entry zone, and/or other particular regions of the spinal column to control pain, the stimulation may in some instances be directed to other neurological structures and/or target other neural populations of the spinal cord. Some embodiments can have configurations, components, and/or procedures different than those described in this section, and other embodiments may eliminate particular components or procedures. Accordingly, the present technology may encompass other embodiments with additional elements and/or steps, and/or may encompass other embodiments without several of the features or steps shown and described below with reference to
In general terms, aspects of many of the following embodiments are directed to simplifying the determination of whether a patient is responsive to the therapeutic effects of paresthesia-free SCS therapies, thereby allowing permanent implantation of a signal generator in less time than is required for conventional procedures. As such, it is expected that the techniques described below with reference to
As described above, a form of high frequency SCS therapy has been developed that does not cause paresthesia. Further, it has been found that there may be a delay before high frequency SCS provides a patient with effective pain relief. Therefore, the patient and practitioner may not immediately know if a patient is a responder to the high frequency SCS therapy. This situation does not exist with conventional SCS because the paresthesia generated by conventional SCS results in an immediate or near-immediate response in the patients, although the optimal settings may take some time to determine. Accordingly, conventional SCS deployment techniques include testing various signal amplitudes in sequence to determine which produces pain relief. Such techniques are not as efficient for high frequency SCS screening. In particular, high frequency SCS deployment techniques include waiting a delay period (usually 1-2 days) at each amplitude setting and repeating the process at a new amplitude setting until pain relief is achieved. Consequently, conventional trial period processes can take days or weeks (depending on the number of amplitudes tested) when used in the context of some high frequency therapy techniques. Embodiments of the technology disclosed herein can provide an advantage over conventional techniques by detecting whether and how the patient's sensory threshold changes over a short period of time.
2.0 Representative Systems
The signal generator 101 can transmit signals (e.g., electrical signals) to the signal delivery devices 110 that up-regulate (e.g., excite) and/or down-regulate (e.g., suppress) target nerves. As used herein, and unless otherwise noted, the terms “modulate,” “modulation,” “stimulate,” and “stimulation” refer generally to signals that have either of the foregoing types of effects on the target nerves. The signal generator 101 (and/or other system components) can include a machine-readable (e.g., computer-readable) medium containing instructions for generating and transmitting suitable therapy signals. The signal generator 101 and/or other elements of the system 100 can include one or more processor(s) 107, memory unit(s) 108, and/or input/output device(s) 112. Accordingly, the process of providing stimulation signals, providing guidance information for positioning the signal delivery devices 110, and/or executing other associated functions (including selecting parameter values and/or screening responders) can be performed automatically by computer-executable instructions contained by computer-readable media located at the pulse generator 101 and/or other system components. Such processes can be performed as part of an overall screening process (e.g., to distinguish responders from non-responders) and/or as part of a longer term therapy regimen (e.g., for patients who have been identified as responders or potential responders). The signal generator 101 can include multiple portions, elements, and/or subsystems (e.g., for directing signals in accordance with multiple signal delivery parameters), carried in a single housing, as shown in
The signal generator 101 can also receive and respond to an input signal received from one or more sources. The input signals can direct or influence the manner in which the therapy instructions are selected, executed, updated and/or otherwise performed. Accordingly, the input/output devices 112 can include one or more sensors (one is shown schematically in
In some embodiments, the signal generator 101 can obtain power to generate the therapy signals from an external power source 103. The external power source 103 can transmit power to the implanted signal generator 101 using electromagnetic induction (e.g., RF signals). For example, the external power source 103 can include an external coil 104 that communicates with a corresponding internal coil (not shown) within the implantable signal generator 101. The external power source 103 can be portable for ease of use. In some embodiments, the external power source 103 can by-pass an implanted signal generator (e.g., eliminating the need for the implanted signal generator) and generate a therapy signal directly at the signal delivery device 110 (or via signal relay components). Such a signal generator can be configured for long-term use, e.g., by having a wearable configuration in which it is continuously available to direct the therapy signal to the implanted signal delivery device.
In some embodiments, the signal generator 101 can obtain the power to generate therapy signals from an internal power source, in addition to or in lieu of the external power source 103. For example, the implanted signal generator 101 can include a non-rechargeable battery or a rechargeable battery to provide such power. When the internal power source includes a rechargeable battery, the external power source 103 can be used to recharge the battery. The external power source 103 can in turn be recharged from a suitable power source (e.g., conventional wall power).
During at least some procedures, an external stimulator or trial modulator 105 can be coupled to the signal delivery devices 110 during an initial portion of the procedure, prior to implanting the signal generator 101. For example, a practitioner (e.g., a physician and/or a company representative) can use the trial modulator 105 to vary the stimulation parameters provided to the signal delivery elements 110 in real time, and select optimal or particularly efficacious parameters. These parameters can include the location from which the electrical signals are emitted, as well as the characteristics of the electrical signals provided to the signal delivery devices 110. In a typical process, the practitioner uses a cable assembly 120 to temporarily connect the trial modulator 105 to the signal delivery devices 110. The practitioner can test the efficacy of the signal delivery devices 110 in an initial position. The practitioner can then disconnect the cable assembly 120 (e.g., at a connector 122), reposition the signal delivery devices 110, and reapply the electrical signals. This process can be performed iteratively until the practitioner obtains the desired position for the signal delivery devices 110. Optionally, the practitioner may move the partially implanted signal delivery devices 110 without disconnecting the cable assembly 120. Furthermore, in some embodiments, the iterative process of repositioning the signal delivery devices 110 and/or varying the therapy parameters may not be performed, or may be performed automatically, as discussed in greater detail later.
The pulse generator 101, the lead extension 102, the trial modulator 105 and/or the connector 122 can each include a receiving element 109. Accordingly, the receiving elements 109 can be implantable elements, or the receiving elements 109 can be integral with an external patient treatment element, device or component (e.g., the trial modulator 105 and/or the connector 122). The receiving elements 109 can be configured to facilitate a simple coupling and decoupling procedure between the signal delivery devices 110, the lead extension 102, the pulse generator 101, the trial modulator 105, and/or the connector 122. The receiving elements 109 can be at least generally similar in structure and function to those described in U.S. Patent Publication No. 2013/0116754, incorporated herein by reference.
After the signal delivery elements 110 are implanted, the patient 190 can receive therapy via signals generated by the trial modulator 105, generally for a limited period of time. Traditionally, the patient 190 receives such therapy for one week. However, with the deployment methods disclosed herein, this time may be reduced, e.g., to a period of 1-2 hours. During this time, the patient can wear the cable assembly 120 and the trial modulator 105 outside the body, or (because the screening technique can be completed in a short period of time), the trial modulator 105 can rest on a table while the patient undergoes the screening process. Assuming the trial therapy is effective or shows the promise of being effective, the practitioner then replaces the trial modulator 105 with the implanted signal generator 101, and programs the signal generator 101 with signal delivery parameters, e.g., selected based on the experience gained during the trial period and/or other sources. Optionally, the practitioner can also replace the signal delivery elements 110. Once the implantable signal generator 101 has been positioned within the patient 190, the signal delivery parameters provided by the signal generator 101 can still be updated remotely via a wireless physician's programmer (e.g., a physician's laptop, a physician's remote or remote device, etc.) 117 and/or a wireless patient programmer 106 (e.g., a patient's laptop, patient's remote or remote device, etc.). Generally, the patient 190 has control over fewer parameters than does the practitioner. For example, the capability of the patient programmer 106 may be limited to starting and/or stopping the signal generator 101, and/or adjusting the signal amplitude.
In any of the foregoing embodiments, the parameters in accordance with which the signal generator 101 provides signals can be adjusted during portions of the therapy regimen. For example, the frequency, amplitude, pulse width and/or signal delivery location can be adjusted in accordance with a preset program, patient and/or physician inputs, and/or in a random or pseudorandom manner. Such parameter variations can be used to address a number of potential clinical situations, including changes in the patient's perception of pain, changes in the preferred target neural population, and/or patient accommodation or habituation. Certain aspects of the foregoing systems and methods may be simplified or eliminated in particular embodiments of the present disclosure. Further aspects of these and other expected beneficial results are detailed in U.S. Pat. No. 8,712,533, incorporated herein by reference.
3.0 Representative Techniques
A form of high frequency SCS therapy has recently been determined to deliver therapy without generating paresthesia or unwanted pain or other sensory or motor effects to achieve effective therapy. (Such high frequency SCS therapy is described in more detail in the above-incorporated U.S. Pat. No. 8,712,533.) Aspects of the present technology are directed to techniques and systems for detecting whether a patient is a responder, despite the absence of paresthesia.
In block 206, a practitioner conducts the trial. As will be described in greater detail below, at least a portion of the trial can include detecting the patient's sensory stimulation threshold (and/or changes in the threshold), and, on at least this basis, determining if the patient is likely a responder. This determination is made in block 208. If the patient is a likely responder, block 210 includes implanting a signal generator to provide long-term therapy to the patient. If the patient does not respond, then block 212 can include identifying an alternate therapy.
While the data collection procedure shown in
The patients, who were already receiving electrical therapy at a frequency of 10 kHz, initially underwent an assessment to collect baseline information. Each patient then received electrical therapy in accordance with each of three different therapy programs, with each program delivered over the course of four days. Each program included a signal frequency, pulse width, amplitude, and signal delivery electrode or electrodes. For each program, the therapy signal was delivered at a frequency of 10 kHz and a pulse width of 30 microseconds. The electrodes to which the therapy signal was directed varied from one program to the next. Patients received the programs in a random order. After the patients were tested at each of the programs, the patient data were collected and assessed.
In addition to collecting patient pain scores, the procedure included collecting patient sensory threshold data.
Each patient received sensory threshold detection or test signal at a frequency of 5 kHz and a pulse width of 80 microseconds. The patients' sensory threshold was assessed at each of the three programs shown in
The sensory threshold was determined by increasing the amplitude of the test signal that was delivered to the patient, until the patient received a signal-induced sensation. Typically, the sensation was one or more of tingling, vibration, tapping, or pinging. As is shown in
Referring now to
In addition to testing the patients' sensory threshold levels, the clinical study included a test of sensation intensity. In particular, it was found that the intensity of the sensation perceived by the patient can change over time.
Based on the foregoing data, it is believed that detecting a patient's adaptation to a high frequency threshold test signal (even, as in the present case, if not at the same frequency as the associated therapy signal) is correlated with the patient's pain reduction when receiving a high frequency therapy signal. As a result, it is expected that detecting/observing the patient's adaptation behavior can be used to screen likely responders to high frequency therapy from likely non-responders. It is further expected that the foregoing results will also obtain if the same (high) frequency value is used for both detecting adaptation and administering therapy.
Another result of the foregoing data, illustrated in
Further representative embodiments of the presently disclosed technology are described below. One such embodiment includes a method for deploying a patient therapy system, that further includes implanting, in a patient's spinal cord region, at least one signal delivery device having at least one signal delivery contact. The method can further include connecting an external signal generator to the at least one signal delivery device, and evaluating the patient's sensory perception (e.g., threshold and/or values and/or changes in values, and/or as a function of the signal delivery contact(s) to which the sensory threshold test signal is delivered. Based on the patient's sensory response (e.g., a low sensory threshold and/or a reduction in perceived intensity over time), the process can further include implanting an implantable signal generator in the patient to deliver electrical therapy on a longer term basis. Furthermore, if the patient's sensory threshold is different (e.g., lower) for one electrode (or electrode bipole or other combination) than for another, the practitioner can select that one electrode (or electrode combination) for long term therapy. This approach can apply to other signal delivery parameters as well.
Several embodiments of the present technology have been described in the context of changes in a characteristic of patient sensory response, e.g., changes in the patents' sensory threshold and/or changes in the patients' perceived sensation intensity. As was also described above, in other embodiments, the correlation can be applied to a value or level of the sensory response characteristic, in addition to or in lieu of a change in the value. For example, in
The electrical therapy signal can include any of a number of suitable amplitudes and pulse widths, in suitable combination with any of the frequencies described herein. In particular embodiments, representative current amplitudes for the therapy signal are from 0.1 mA to 20 mA, or 0.5 mA to 10 mA, or 0.5 mA to 7 mA, or 0.5 mA to 5 mA. Representative pulse widths range from about 10 microseconds to about 333 microseconds, about 10 microseconds to about 166 microseconds, about 20 microseconds to about 100 microseconds, about 30 microseconds to about 100 microseconds, about 30 microseconds to about 35 microseconds, and about 30 microseconds to about 40 microseconds. Further representative pulse widths include pulse widths from 10-50 microseconds, 20-40 microseconds, 25-35 microseconds, and 30 microseconds.
While the sensory threshold test signal in some embodiments is delivered at 5 kHz (e.g., to allow pulse widths of 80 microseconds), the frequency of the test signal can have other values (generally above 1.2 kHz) in other embodiments. It is expected that the adaptation time may vary with frequency, e.g., may be longer at lower frequencies. The pulse widths and duty cycles of the test signals can also be varied from the specific values disclosed herein.
From the foregoing, it will be appreciated that specific embodiments of the technology have been described herein for purposes of illustration, but that various modifications may be made without deviating from the technology. For example, test signals can have other signal parameters, as discussed above. In still further embodiments, the foregoing techniques can be used in the context of a signal generator that is external during the long-term treatment regimen (e.g., in addition to a trial period). Such a signal generator can transmit pulses (or energy for pulses) directly to an implanted signal delivery device through the patient's skin.
Certain aspects of the technology described in the context of particular embodiments may be combined or eliminated in other embodiments. For example, the foregoing techniques can be used to screen patients, identify particular electrodes (and/or other signal delivery parameters) for stimulation, or both. While the results disclosed herein were obtained for particular combinations of frequency and pulse width, in other embodiments, other combinations of frequency and pulse width, within the ranges described above, can be used. The signal can be delivered, during testing, at a duty cycle of 200 milliseconds, followed by a one second off period, as discussed above, or at other suitable duty cycles. Many of the operations (e.g., receiving information, making a determination, and presenting and/or acting on the determination) described above can suitably be performed by one or more machine-readable media, carried by system components positioned within or external to the patient. In some cases, the operations can be distributed over multiple machine-readable media, with one or more of the media positioned within the patient and/or one or more of the media positioned external to the patient. Further, while advantages associated with certain embodiments of the technology have been described in the context of those embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the present technology. Accordingly, the present disclosure and associated technology can encompass other embodiments not expressly shown or described herein.
To the extent any materials incorporated by reference herein conflict with the present disclosure, the present disclosure controls. As used herein, the term “between” in the context of a range includes the endpoints of the range. As used herein, the phrase “and/or” as in “A and/or B” refers to A alone, B alone, and both A and B.
The present application claims priority to U.S. Provisional Application No. 62/793,738, filed on Jan. 17, 2019, and incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
1597061 | Cultra | Aug 1926 | A |
2622601 | Nemec | Dec 1952 | A |
3195540 | Waller | Jul 1965 | A |
3817254 | Maurer | Jun 1974 | A |
3822708 | Zilber | Jul 1974 | A |
3893463 | Williams | Jul 1975 | A |
4014347 | Halleck et al. | Mar 1977 | A |
4023574 | Nemec | May 1977 | A |
4055190 | Tany et al. | Oct 1977 | A |
4414986 | Dickhudt et al. | Nov 1983 | A |
4535777 | Castel | Aug 1985 | A |
4541432 | Molina-Negro et al. | Sep 1985 | A |
4608985 | Crish et al. | Sep 1986 | A |
4649935 | Charmillot et al. | Mar 1987 | A |
4841973 | Stecker | Jun 1989 | A |
RE33420 | Sussman et al. | Nov 1990 | E |
5002053 | Garcia-Rill | Mar 1991 | A |
5335657 | Terry, Jr. et al. | Aug 1994 | A |
5354320 | Schaldach et al. | Oct 1994 | A |
5514175 | Kim et al. | May 1996 | A |
5562717 | Tippey et al. | Oct 1996 | A |
5643330 | Holsheimer et al. | Jul 1997 | A |
5776170 | MacDonald et al. | Jul 1998 | A |
5806522 | Katims | Sep 1998 | A |
5830151 | Hadzic et al. | Nov 1998 | A |
5853373 | Griffith et al. | Dec 1998 | A |
5893883 | Torgerson | Apr 1999 | A |
5983141 | Sluijter et al. | Nov 1999 | A |
5995872 | Bourgeois | Nov 1999 | A |
6002964 | Feler et al. | Dec 1999 | A |
6014588 | Fitz | Jan 2000 | A |
6027456 | Feler et al. | Feb 2000 | A |
6161044 | Silverstone | Dec 2000 | A |
6167311 | Rezai | Dec 2000 | A |
6176242 | Rise | Jan 2001 | B1 |
6233488 | Hess | May 2001 | B1 |
6238423 | Bardy | May 2001 | B1 |
6246912 | Sluijter et al. | Jun 2001 | B1 |
6341236 | Osorio et al. | Jan 2002 | B1 |
6356786 | Rezai et al. | Mar 2002 | B1 |
6405079 | Ansarinia | Jun 2002 | B1 |
6421566 | Holsheimer | Jul 2002 | B1 |
6440090 | Schallhorn | Aug 2002 | B1 |
6505078 | King et al. | Jan 2003 | B1 |
6510347 | Borkan | Jan 2003 | B2 |
6571127 | Ben-Haim et al. | May 2003 | B1 |
6584358 | Carter et al. | Jun 2003 | B2 |
6609030 | Rezai et al. | Aug 2003 | B1 |
6622048 | Mann | Sep 2003 | B1 |
6721603 | Zabara et al. | Apr 2004 | B2 |
6795737 | Gielen et al. | Sep 2004 | B2 |
6871090 | He et al. | Mar 2005 | B1 |
6885888 | Rezai | Apr 2005 | B2 |
6907295 | Gross et al. | Jun 2005 | B2 |
6923784 | Stein | Aug 2005 | B2 |
6928320 | King | Aug 2005 | B2 |
6950707 | Whitehurst | Sep 2005 | B2 |
6968237 | Doan et al. | Nov 2005 | B2 |
6990376 | Tanagho et al. | Jan 2006 | B2 |
7024246 | Acosta et al. | Apr 2006 | B2 |
7047079 | Erickson | May 2006 | B2 |
7082333 | Bauhahn et al. | Jul 2006 | B1 |
7117034 | Kronberg | Oct 2006 | B2 |
7146224 | King | Dec 2006 | B2 |
7149574 | Yun et al. | Dec 2006 | B2 |
7167750 | Knudson et al. | Jan 2007 | B2 |
7174215 | Bradley | Feb 2007 | B2 |
7180760 | Varrichio et al. | Feb 2007 | B2 |
7206632 | King | Apr 2007 | B2 |
7212865 | Cory | May 2007 | B2 |
7236822 | Dobak, III | Jun 2007 | B2 |
7239912 | Dobak, III | Jul 2007 | B2 |
7252090 | Goetz | Aug 2007 | B2 |
7260436 | Kilgore et al. | Aug 2007 | B2 |
7266412 | Stypulkowski | Sep 2007 | B2 |
7288062 | Spiegel | Oct 2007 | B2 |
7313440 | Miesel | Dec 2007 | B2 |
7324852 | Barolat et al. | Jan 2008 | B2 |
7326181 | Katims | Feb 2008 | B2 |
7333857 | Campbell | Feb 2008 | B2 |
7337005 | Kim et al. | Feb 2008 | B2 |
7346398 | Gross et al. | Mar 2008 | B2 |
7349743 | Tadlock | Mar 2008 | B2 |
7363076 | Yun et al. | Apr 2008 | B2 |
7389145 | Kilgore et al. | Jun 2008 | B2 |
7393351 | Woloszko et al. | Jul 2008 | B2 |
7493172 | Whitehurst et al. | Feb 2009 | B2 |
7502652 | Gaunt et al. | Mar 2009 | B2 |
7580753 | Kim et al. | Aug 2009 | B2 |
7599737 | Yomtov et al. | Oct 2009 | B2 |
7676269 | Yun et al. | Mar 2010 | B2 |
7689289 | King | Mar 2010 | B2 |
7734340 | De Ridder | Jun 2010 | B2 |
7742810 | Moffitt et al. | Jun 2010 | B2 |
7761170 | Kaplan et al. | Jul 2010 | B2 |
7778704 | Rezai | Aug 2010 | B2 |
7813803 | Heruth et al. | Oct 2010 | B2 |
7826901 | Lee et al. | Nov 2010 | B2 |
7860570 | Whitehurst et al. | Dec 2010 | B2 |
7877136 | Moffitt et al. | Jan 2011 | B1 |
7890176 | Jaax et al. | Feb 2011 | B2 |
7933654 | Merfeld et al. | Apr 2011 | B2 |
7937145 | Dobak | May 2011 | B2 |
8010198 | Libbus et al. | Aug 2011 | B2 |
8027718 | Spinner et al. | Sep 2011 | B2 |
8046075 | Rezai | Oct 2011 | B2 |
8060208 | Kilgore et al. | Nov 2011 | B2 |
8082038 | Simon et al. | Dec 2011 | B2 |
8082039 | Kim et al. | Dec 2011 | B2 |
8170675 | Alataris et al. | May 2012 | B2 |
8209021 | Alataris et al. | Jun 2012 | B2 |
8209028 | Skelton et al. | Jun 2012 | B2 |
8224453 | De Ridder | Jul 2012 | B2 |
8255057 | Fang et al. | Aug 2012 | B2 |
8280515 | Greenspan | Oct 2012 | B2 |
8355792 | Alataris et al. | Jan 2013 | B2 |
8355797 | Caparso | Jan 2013 | B2 |
8359102 | Alataris et al. | Jan 2013 | B2 |
8359103 | Alataris et al. | Jan 2013 | B2 |
8380318 | Kishawi et al. | Feb 2013 | B2 |
8396559 | Alataris et al. | Mar 2013 | B2 |
8423147 | Alataris et al. | Apr 2013 | B2 |
8428748 | Alataris et al. | Apr 2013 | B2 |
8509905 | Alataris et al. | Aug 2013 | B2 |
8554326 | Alataris et al. | Oct 2013 | B2 |
8569935 | Kosierkiewicz | Oct 2013 | B1 |
8694109 | Alataris et al. | Apr 2014 | B2 |
8712533 | Alataris et al. | Apr 2014 | B2 |
8712534 | Wei | Apr 2014 | B2 |
8718781 | Alataris et al. | May 2014 | B2 |
8718782 | Alataris et al. | May 2014 | B2 |
8768472 | Fang et al. | Jul 2014 | B2 |
8774926 | Alataris et al. | Jul 2014 | B2 |
8874217 | Alataris et al. | Oct 2014 | B2 |
8874221 | Alataris et al. | Oct 2014 | B2 |
9220889 | Carlton et al. | Dec 2015 | B2 |
9278215 | Thacker et al. | Mar 2016 | B2 |
9283387 | Thacker et al. | Mar 2016 | B2 |
9283388 | Thacker et al. | Mar 2016 | B2 |
9789313 | Lipani | Oct 2017 | B2 |
20020055779 | Andrews | May 2002 | A1 |
20020128700 | Cross | Sep 2002 | A1 |
20030120323 | Meadows et al. | Jun 2003 | A1 |
20030204221 | Rodriguez et al. | Oct 2003 | A1 |
20040015202 | Chandler et al. | Jan 2004 | A1 |
20040034394 | Woods et al. | Feb 2004 | A1 |
20040039425 | Greenwood-Van Meerveld | Feb 2004 | A1 |
20040073273 | Gluckman et al. | Apr 2004 | A1 |
20040162590 | Whitehurst et al. | Aug 2004 | A1 |
20040167584 | Carroll et al. | Aug 2004 | A1 |
20040210270 | Erickson | Oct 2004 | A1 |
20050033381 | Carter et al. | Feb 2005 | A1 |
20050038489 | Grill | Feb 2005 | A1 |
20050060001 | Singhal et al. | Mar 2005 | A1 |
20050113882 | Cameron et al. | May 2005 | A1 |
20050119713 | Whitehurst et al. | Jun 2005 | A1 |
20050143789 | Whitehurst et al. | Jun 2005 | A1 |
20050153885 | Yun et al. | Jul 2005 | A1 |
20050246006 | Daniels | Nov 2005 | A1 |
20060004422 | De Ridder | Jan 2006 | A1 |
20060041285 | Johnson | Feb 2006 | A1 |
20060074456 | Pyles et al. | Apr 2006 | A1 |
20060095088 | De Ridder | May 2006 | A1 |
20060100671 | Ridder | May 2006 | A1 |
20060161219 | Mock et al. | Jul 2006 | A1 |
20060161235 | King | Jul 2006 | A1 |
20060190048 | Gerber | Aug 2006 | A1 |
20060229687 | Goetz et al. | Oct 2006 | A1 |
20060253182 | King | Nov 2006 | A1 |
20070021803 | Deem et al. | Jan 2007 | A1 |
20070032827 | Katims | Feb 2007 | A1 |
20070039625 | Heruth et al. | Feb 2007 | A1 |
20070049991 | Klostermann et al. | Mar 2007 | A1 |
20070060954 | Cameron et al. | Mar 2007 | A1 |
20070066997 | He et al. | Mar 2007 | A1 |
20070073353 | Rooney et al. | Mar 2007 | A1 |
20070073354 | Knudson et al. | Mar 2007 | A1 |
20070106337 | Errico et al. | May 2007 | A1 |
20070150034 | Rooney et al. | Jun 2007 | A1 |
20070156183 | Rhodes | Jul 2007 | A1 |
20070179559 | Giftakis et al. | Aug 2007 | A1 |
20070179579 | Feler et al. | Aug 2007 | A1 |
20070239226 | Overstreet | Oct 2007 | A1 |
20070244522 | Overstreet | Oct 2007 | A1 |
20070299482 | Littlewood et al. | Dec 2007 | A1 |
20080033511 | Dobak | Feb 2008 | A1 |
20080103570 | Gerber | May 2008 | A1 |
20080167697 | Johnson | Jul 2008 | A1 |
20080183259 | Bly et al. | Jul 2008 | A1 |
20080234791 | Arie et al. | Sep 2008 | A1 |
20090036945 | Chancellor et al. | Feb 2009 | A1 |
20090054962 | Lefler et al. | Feb 2009 | A1 |
20090132010 | Kronberg | May 2009 | A1 |
20090157141 | Chiao et al. | Jun 2009 | A1 |
20090157149 | Wahlgren et al. | Jun 2009 | A1 |
20090198306 | Goetz et al. | Aug 2009 | A1 |
20090204173 | Fang et al. | Aug 2009 | A1 |
20090281595 | King et al. | Nov 2009 | A1 |
20090287274 | De Ridder | Nov 2009 | A1 |
20090326611 | Gillbe | Dec 2009 | A1 |
20100016929 | Prochazka | Jan 2010 | A1 |
20100036454 | Bennett et al. | Feb 2010 | A1 |
20100094375 | Donders et al. | Apr 2010 | A1 |
20100125313 | Lee et al. | May 2010 | A1 |
20100137938 | Kishawi et al. | Jun 2010 | A1 |
20100191307 | Fang et al. | Jul 2010 | A1 |
20100241190 | Kilgore et al. | Sep 2010 | A1 |
20100274312 | Alataris et al. | Oct 2010 | A1 |
20100274314 | Alataris et al. | Oct 2010 | A1 |
20100274315 | Alataris et al. | Oct 2010 | A1 |
20100274316 | Alataris et al. | Oct 2010 | A1 |
20100274317 | Parker et al. | Oct 2010 | A1 |
20100274318 | Walker et al. | Oct 2010 | A1 |
20100274320 | Torgerson | Oct 2010 | A1 |
20100274326 | Chitre et al. | Oct 2010 | A1 |
20100324630 | Lee et al. | Dec 2010 | A1 |
20100331916 | Parramon et al. | Dec 2010 | A1 |
20110009919 | Carbunaru et al. | Jan 2011 | A1 |
20110009923 | Lee | Jan 2011 | A1 |
20110022114 | Navarro | Jan 2011 | A1 |
20110184486 | De Ridder | Jul 2011 | A1 |
20110184488 | De Ridder | Jul 2011 | A1 |
20110201977 | Tass | Aug 2011 | A1 |
20110276107 | Simon et al. | Nov 2011 | A1 |
20110282412 | Glukhovsky et al. | Nov 2011 | A1 |
20120089200 | Ranu et al. | Apr 2012 | A1 |
20120172946 | Alataris et al. | Jul 2012 | A1 |
20120277833 | Gerber et al. | Nov 2012 | A1 |
20120283797 | De Ridder | Nov 2012 | A1 |
20130006325 | Woods et al. | Jan 2013 | A1 |
20130023951 | Greenspan | Jan 2013 | A1 |
20130041425 | Fang et al. | Feb 2013 | A1 |
20130066411 | Thacker et al. | Mar 2013 | A1 |
20130116754 | Sharma et al. | May 2013 | A1 |
20130172955 | Alataris et al. | Jul 2013 | A1 |
20130204173 | Kelly et al. | Aug 2013 | A1 |
20130204323 | Thacker et al. | Aug 2013 | A1 |
20130211487 | Fang et al. | Aug 2013 | A1 |
20130282078 | Wacnik | Oct 2013 | A1 |
20140031896 | Alataris et al. | Jan 2014 | A1 |
20140276549 | Osorio | Sep 2014 | A1 |
20140316484 | Edgerton et al. | Oct 2014 | A1 |
20150217116 | Parramon et al. | Aug 2015 | A1 |
20160082252 | Hershey et al. | Mar 2016 | A1 |
20160121109 | Edgerton | May 2016 | A1 |
20160175594 | Min et al. | Jun 2016 | A1 |
20170036023 | Parker | Feb 2017 | A1 |
20170095667 | Yakovlev | Apr 2017 | A1 |
20170165485 | Sullivan et al. | Jun 2017 | A1 |
20170291031 | Lee | Oct 2017 | A1 |
20180272132 | Subbaroyan | Jan 2018 | A1 |
20200139138 | Sit et al. | May 2020 | A1 |
20200254255 | Lee | Aug 2020 | A1 |
20200324113 | Fisher | Oct 2020 | A1 |
20200353253 | Subbaroyan | Nov 2020 | A1 |
Number | Date | Country |
---|---|---|
2449546 | Nov 2008 | GB |
2007528774 | Oct 2007 | JP |
WO-02065896 | Aug 2002 | WO |
WO-02092165 | Nov 2002 | WO |
WO-2007082382 | Jul 2007 | WO |
WO-2007117232 | Oct 2007 | WO |
WO-2008039982 | Apr 2008 | WO |
WO-2008045434 | Apr 2008 | WO |
WO-2008121891 | Oct 2008 | WO |
WO-2011014570 | Feb 2011 | WO |
WO-2013116368 | Aug 2013 | WO |
WO-2014146082 | Sep 2014 | WO |
Entry |
---|
International Search Report and Written Opinion for International Patent Application No. PCT/US2020/014160, Applicant: Nevro Corp., dated Jun. 4, 2020, 13 pages. |
Alo et al., “New Trends in Neuromodulation for the Management of Neuropathic Pain,” Neurosurgery, vol. 50, No. 4, Apr. 2002, 15 pages. |
Bahdra et al., Stimulation of High-Frequency Sinusoidal Electrical Block of Mammalian Myelinated Axons, J Comput Neurosco, 22:313-326, 2007. |
Barolat et al., “Multifactorial Analysis of Epidural Spinal Cord Stimulation,” Sterotactic and Functional Neurosurgery, 1991; 56: 77-103. |
Bhadra et al., “High Frequency electrical conduction block of the pudendal nerve,” Journal of Neural Engineering—Institute of Physics Publishing, 2006, 8 pages. |
Bhadra MD, Niloy et al., “High-Frequency Electrical Conduction Block of Mammalian Peripheral Motor Nerve,” Muscle and Nerve, Dec. 2005, 9 pages. |
Boger et al., “Bladder Voiding by Combined High Frequency Electrical Pudendal Nerve Block and Sacral Root Stimulation,” Neurourology and Urodynamics, 27, 2008, 5 pages. |
Bowman and McNeal, Response of Single Alpha Motoneurons to High-Frequency Pulse Trains, Appl. Neurophysiol. 49, p. 121-138, 1986, 10 pages. |
Burton, Charles, “Dorsal Column Stimulation: Optimization of Application,” Surgical Neurology, vol. 4, No. 1, Jul. 1975, 10 pages. |
Cuellar et al., “Effect of High Frequency Alternating Current on Spinal Afferent Nociceptive Transmission,” Neuromodulation: Technology at the Neural Interface, 2012, 10 pages. |
DeRidder et al., “Are Paresthesias necessary for pain suppression in SCS—Burst Stimulation,” Brain, Brain Research Center Antwerp of Innovative and Interdisciplinary Neuromodulation, 2010, 27 pages. |
DeRidder et al., “Burst Spinal Cord Stimulation: Toward Paresthesia-Free Pain Suppression,” www.neurosurgery-online.com, vol. 66, Nos. 5, May 2010, 5 pages. |
Grill, Warren et al., “Stimulus Waveforms for Selective Neural Stimulation,” IEEE Engineering in Medicine and Biology, Jul./Aug. 1995, pp. 375-385. |
Holsheimer—Effectiveness of Spinal Cord Stimulation in the Management of Chronic Pain: Analysis of Technical Drawbacks and Solutions, Neurosurgery, vol. 40, No. 5, May 1997, pp. 990-999. |
Hopp et al., “Effect of anodal blockade of myelinated fibers on vagal c-fiber afferents,” American Journal Physiological Society, Nov. 1980; 239(5), 9 pages. |
Hoppenstein, Reuben, “Electrical Stimulation of the Ventral and Dorsal Columns of the Spinal Cord for Relief of Chronic Intractable Pain: Preliminary Report,” Surgical Neurology, vol. 4, No. 1, Jul. 1975, 9 pages. |
Huxely et al., “Excitation and Conduction in Nerve: Quantitative Analysis,” Science, Sep. 11, 1964; 145: 1154-9. |
Jang et al., “Analysis of Failed Spinal Cord Stimulation Trails in the Treatment of Intractable Chronic Pain,” J. Korean Neurosurg Soc 43, 2008, 5 pages. |
Kilgore et al. “Nerve Conduction Block Utilizing High-Frequency Alternating Current” Medical & Biology Engineering and Computing, 2004, vol. 24, pp. 394-406. |
Kilgore et al. “Reversible Nerve Conduction Block Using Kilohertz Frequency Alternating Current,” Neuromodulation Technology at the Neural Interface, International Neuromodulation Society, 2013, 13 pages. |
Kumar et al., “Spinal Cord Stimulation in Treatment of Chronic Benign Pain: Challenges in Treatment Planning and Present Status, a 22-Year Experience,” Neurosurgery, vol. 58, No. 3, Mar. 2006, 16 pages. |
Lachance et al., “Stimulation-induced ectopicity and propagation windows in model damaged axons,” J. Comput Neurosci, 2014, 9 pages. |
Linderoth et al., “Mechanisms of Spinal Cord Stimulation in Painful Syndromes: Role of Animal Models,” Pain Medicine, vol. 7, No. S1, 2006, 13 pages. |
Linderoth et al., “Physiology of Spinal Cord Stimulation: Review and Update,” Neuromodulation, vol. 2, No. 3, 1999, 15 pages. |
Mediati, R.D., , “Mechanisms of Spinal Cord Stimulation,” Florence, Oct. 2, 2002, 31 pages. |
Melzack, Ronald et al., “Pain Mechanisms: A New Theory,” Science, vol. 150, No. 3699, Nov. 19, 1965, 9 pages. |
Muller and Hunsperger, “Helvetica Physiologica Acta—Reversible Blockierung der Erregungsleitung im Nerven durch Mittelfrequenz- Daverstrom,” Schwabe & Co. Basel, vol. 25, Fasc. 1, 1967, 4 pages. |
North et al., “Failed Back Surgery Syndrome: 5-year Follow-Up after Spinal Cord Stimulator Implantation,” Neurosurgery, Official Journal of the Congress of Neurological Surgeons, vol. 28, No. 5, May 1991, 9 pages. |
North et al., “Spinal Cord Stimulation for Axial Low Back Pain,” Spine, vol. 30, No. 12, 2005, 7 pages. |
North et al., “Spinal Cord Stimulation for Chronic, Intractable Pain: Experience over Two Decades,” Neurosurgery, vol. 32, No. 2, Mar. 1993, 12 pages. |
Oakley, John C., “Spinal Cord Stimulation Mechanisms of Action,” Spine vol. 27, No. 22, copyright 2002, 10 pages. |
Perruchoud et al., “Analgesic Efficacy of High-Frequency Spinal Cord Stimulation: A Randomized Double-Blind Placebo-Controlled Study,” Neuromodulation: Technology at Neural Interface, International Neuromodulation Society, 2013, 7 pages. |
Shealy MD, C. Norman et al., “Electrical Inhibition of Pain by Stimulation of the Dorsal Columns: Preliminary Clinical Report,” Anesthesia and Analgesia . . . Current Researches, vol. 446, No. 4, Jul.-Aug. 1967, 3 pages. |
Simpson, BA, “Spinal Cord Stimulation in 60 cases of Intractable Pain.” Journal of Neurology, Neurosurgery and Psychiatry, 1991; 54 pp. 196-199. |
Simpson, BA, “Spinal Cord Stimulation.” British Journal of Neurosurgery, 1997, Feb. 11 (1), 5-11, 7 pages. |
Solomonow et al., “Control of Muscle Contractile Force through Indirect High-Frequency Stimulation,” AM Journal of Physical Medicine, 1983, vol. 62, No. 3, pp. 71-82. |
Tanner, J.A., “Reversible blocking of nerve conduction by alternating-current excitation,” Nature, Aug. 18, 1962; 195: 712-3. |
Tiede et al., “Novel Spinal Cord Stimulation Parameters in Patients with Predominate Back Pain,” Neuromodulation: Technology at the Neural Interface, 2013, 6 pages. |
Urban et al., “Percutaneous epidural stimulation of the spinal cord for relief of pain—Long Term Results,” Journal of Neurosurgery, vol. 48, Mar. 1978, 7 pages. |
Van Butyen et al., “High Frequency Spinal Cord Stimulation for the Treatment of Chronic Back Pain Patients: Results of a Prospective Multicenter European Clinical Study,” Neuromodulation Technology at the Neural Interface, International Neuromodulation Society, 2012, 8 pages. |
Van Den Honert et al. “Generation of Unidirectionally Propagated Action Potentials Nerve by Brief Stimuli” Science, vol. 26, pp. 1311-1312. |
Van Den Honert, Mortimer JT, “A Technique for Collision Block of Peripheral Nerve: Frequency Dependence,” MP-11 IEEE Trans. Biomed, Eng. 28: 379-382, 1981. |
Wallin et al., “Spinal Cord Stimulation inhibits long-term potentiation of spinal wide dynamic range neurons,” Elsevier Science B.V., Brain Research, 5 pages 2003. |
Wolter et al., “Continuous Versus Intermittent Spinal Cord Stimulation: An Analysis of Factors Influencing Clinical Efficacy,” Neuromodulation: Technology at Neural Interface, www.neuromodulationjournal.com, 2011, 8 pages. |
Woo MY, Campbell B. “Asynchronous Firing and Block of Peripheral Nerve Conduction by 20KC Alternating Current,” Los Angeles Neuro Society, Jun. 1964; 87-94, 5 pages. |
Zhang et al., “Simulation Analysis of Conduction Block in Myelinated Axons Induced by High-Frequency Biphasic Rectangular Pulses,” IEEE Transactions on Biomedical Engineering, vol. 53., No. 7, Jul. 2006, 4 pages. |
Zhu et al., “Changes in functional properties of A-type but not C-type sensory neurons in vivo in a rat model of peripheral neuropathy,” Journal of Pain Research, Dovepress, 2012, 18 pages. |
Zhu et al., “Early Demyelination of Primary A—Fibers Induces a Rapid-Onset of Neuropathic Pain in Rat,” Neuroscience 200, 2012, 13 pages. |
Zhu et al., “Excitability of Aβ sensory neurons is altered in an animal model of peripheral neuropathy,” BMC Neuroscience, 13:15, 2012, 15 pages. |
U.S. Appl. No. 15/606,869, filed May 26, 2017, Lee. |
National Institute of Neurological Disorders and Stroke (NINDS), “Paresthesia,” https://www.ninds.gov/Disorders/All-Disorders/Paresthesia-Information-Page#disorders-r3>, 2014, 2 pages. |
Seattle Pain Relief Now Helping Diabetic Neuropathy Patients Restore Sensation with Spinal Cord Stimulation, PRWeb Online Visibility from Vocus, https://www.prweb.com/releases/diabetic-neuopathy/seattle-tacoma-wa/prweb13080906.htm, 2015, 2 pages. |
Number | Date | Country | |
---|---|---|---|
20200254255 A1 | Aug 2020 | US |
Number | Date | Country | |
---|---|---|---|
62793738 | Jan 2019 | US |